Granules India Ltd Stock Price Today (NSE: GRANULES)
Fundamental Score
Granules India Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Granules India Ltd share price today is ₹741.40, down 0.93% on NSE/BSE as of 17 June 2026. Granules India Ltd (GRANULES) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹13.79K (Cr). The 52-week high for GRANULES share price is ₹804.30 and the 52-week low is ₹432.60. At a P/E ratio of 27.00x, GRANULES is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 13.86% and a debt-to-equity ratio of 0.45.
Granules India Ltd Share Price Chart — NSE/BSE Historical Performance
Granules India Ltd share price chart: 11.64% return over the past month. 52-week high ₹804.30, 52-week low ₹432.60.
Granules India Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹779.50 | ₹787.25 | ₹768.75 | ₹777.55 | 4.27L (Cr) | |
| ₹780.00 | ₹793.00 | ₹770.60 | ₹779.00 | 7.48L (Cr) | |
| ₹795.00 | ₹804.30 | ₹768.55 | ₹773.85 | 11.70L (Cr) | |
| ₹782.60 | ₹782.60 | ₹782.60 | ₹782.60 | 0.00 (Cr) | |
| ₹760.00 | ₹800.00 | ₹754.85 | ₹782.60 | 119.94L (Cr) | |
| ₹758.50 | ₹778.75 | ₹752.55 | ₹756.50 | 7.36L (Cr) | |
| ₹753.25 | ₹763.30 | ₹753.05 | ₹758.40 | 4.16L (Cr) | |
| ₹766.80 | ₹771.50 | ₹750.00 | ₹751.95 | 6.68L (Cr) | |
| ₹763.90 | ₹769.30 | ₹757.00 | ₹764.20 | 5.00L (Cr) | |
| ₹763.95 | ₹771.80 | ₹754.50 | ₹758.65 | 6.09L (Cr) |
Granules India Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹780.00 | ₹793.00 | ₹768.75 | ₹777.55 | -0.31% | |
| ₹699.70 | ₹804.30 | ₹690.05 | ₹773.85 | +10.60% | |
| ₹629.00 | ₹730.80 | ₹602.20 | ₹699.70 | +11.24% | |
| ₹569.00 | ₹640.00 | ₹547.40 | ₹620.40 | +9.03% | |
| ₹552.90 | ₹606.95 | ₹537.65 | ₹582.25 | +5.31% | |
| ₹600.40 | ₹627.00 | ₹531.80 | ₹570.60 | -4.96% | |
| ₹562.50 | ₹624.70 | ₹540.55 | ₹598.50 | +6.40% | |
| ₹565.95 | ₹578.05 | ₹529.85 | ₹556.10 | -1.74% | |
| ₹522.70 | ₹587.20 | ₹522.70 | ₹565.60 | +8.21% | |
| ₹494.00 | ₹553.00 | ₹492.45 | ₹517.00 | +4.66% | |
| ₹475.95 | ₹512.90 | ₹432.60 | ₹492.25 | +3.42% | |
| ₹496.80 | ₹511.75 | ₹461.45 | ₹474.90 | -4.41% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Granules is a hold, betting on backward integration and CDMO growth, but execution risks and USFDA concerns temper enthusiasm.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Granules India is , close to its 52-week high of Analysts estimate Q4 FY26 revenue to be between -1,380 Cr and PAT between -195 Cr. The board is expected to consider a final dividend in May 2026. Granules officially confirmed it does not qualify as a 'Large Corporate' under SEBI rules.
CORE STORY (THE REAL GAME)
Granules is being priced as a backward integration play with a growing CDMO business, not just a generics manufacturer. The market is watching its ability to scale up the Senn Chemicals acquisition and capitalize on injectables.
- Q4 results and FY27 guidance expected in May 2026
- Injectables acquisition strategy in play
- Strong Q3 FY26 results with 22% revenue growth
- Successful injectables acquisition
- Strong Q4 FY26 results exceeding analyst estimates
- Positive USFDA inspection outcome for Gagillapur facility
- USFDA observations at Gagillapur facility
- Slower-than-expected ramp-up of Senn Chemicals
- Failure to secure injectables acquisition target
FII increased stake by 0.85%, while DII decreased stake by 5.61%
Indian pharma exports are growing, projected to reach $130 billion by 2030, but face global pricing pressures.
Profit converting to cash, Free Cash Flow 5Y: ₹782.23 Cr
Expect sustained growth driven by backward integration and CDMO, with injectables as a potential upside. Monitor USFDA inspections and acquisition progress.
Primary Thesis Risk
USFDA issues or CDMO ramp-up delays could derail the growth story.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Granules India Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Granules India Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GRANULES across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Excellent ROCE Performance (15.14%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (20.99%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (34.33%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (34.18%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Interest Coverage (7.43x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹782.23 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 32.00%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Granules India Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Granules India Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Granules India LtdGranules India ...Selected✓ GRANULES • 532482 | 54.2/100 | ₹741.40₹741 | ₹13793.10₹13793.10 | 27.00Average 27.0 Average | 13.86%Average 13.86% Average | 15.14%Good 15.14% Good | 0.45Excellent 0.5 Excellent | 8.80%Good 8.80% Good | 11.52%Good 11.52% Good | 0.26% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Granules India Ltd PE Ratio History
Historical price-to-earnings ratio for GRANULES — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹16.72 | ₹592.30 | 35.4x |
| FY 2023 | ₹21.00 | ₹405.45 | 19.3x |
| FY 2022 | ₹16.60 | ₹318.80 | 19.2x |
| FY 2021 | ₹21.95 | ₹336.20 | 15.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Granules India Ltd Dividend History
Annual cash dividends paid by GRANULES — dividend yield 0.26%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹36.35 Cr |
| FY 2024 | ₹36.31 Cr |
| FY 2023 | ₹18.62 Cr |
| FY 2022 | ₹37.17 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Granules India Ltd Quarterly Performance
Latest quarterly metrics for GRANULES — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
34.18%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
34.33%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
11.52%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
8.80%
Compounded annual net profit growth over 5 years
Granules India Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GRANULES — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Granules India Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Granules India Ltd (GRANULES) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Granules India Ltd
About GRANULES (Granules India Ltd)
Granules India Ltd is a vertically integrated pharmaceutical company headquartered in Hyderabad, India, with a global footprint. It operates across the entire pharmaceutical value ...chain, from active pharmaceutical ingredients (APIs) to finished dosages (FDs), ensuring quality control and supply chain reliability. Granules specializes in manufacturing a diverse portfolio of essential medications, covering pain management, diabetes treatment, cough and cold remedies, and muscle relaxants. The company is renowned for its commitment to innovation, constantly striving to develop novel drug delivery systems and improve existing formulations. With a focus on sustainability and ethical business practices, Granules India Ltd is dedicated to providing affordable and accessible healthcare solutions to patients worldwide. Granules distinguishes itself through its robust manufacturing capabilities and state-of-the-art facilities, enabling the production of high-quality pharmaceutical products at scale. The company's strengths lie in its process chemistry expertise and efficient manufacturing processes, leading to cost competitiveness and timely delivery. Granules is a significant player in both the Indian and international markets, exporting its products to numerous countries across North America, Europe, Latin America, and Asia. Furthermore, the company emphasizes strategic collaborations and partnerships to expand its market reach and product offerings, solidifying its position as a trusted pharmaceutical supplier. This commitment to quality, affordability, and global reach makes Granules a vital contributor to the healthcare landscape. Granules also invests heavily in research and development, consistently seeking to improve its product portfolio and cater to unmet medical needs. Its R&D efforts focus on developing innovative formulations, improving drug efficacy, and reducing side effects. The company maintains a strong regulatory compliance record, adhering to the highest international standards and guidelines. Through its commitment to continuous improvement and innovation, Granules seeks to remain at the forefront of the pharmaceutical industry and contribute to improved patient outcomes globally. With a focus on affordability, innovation, and quality, Granules India Ltd stands as a reliable partner for healthcare providers and patients.
Company Details
Key Leadership
Corporate Events
GRANULES Share Price: Frequently Asked Questions
What is the current share price of Granules India Ltd?
Granules India Ltd (GRANULES) trades at ₹741.40 on NSE and BSE. Market cap ₹13.79K (Cr). Educational data only.
What is the P/E ratio of Granules India Ltd?
Granules India Ltd has a P/E of 27.00x vs industry average 31.77x.
What is the Bull Run score for Granules India Ltd?
Granules India Ltd has a Bull Run score of 54.2/100 based on 25+ financial parameters.
Does Granules India Ltd pay dividends?
Granules India Ltd has a dividend yield of 0.26%. Past dividends don't guarantee future payments.
What is the ROE of Granules India Ltd?
Granules India Ltd has ROE of 13.86%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Granules India Ltd?
Granules India Ltd has debt-to-equity of 0.45.
Is Granules India Ltd a good investment?
Bull Run gives Granules India Ltd a score of 54.2/100. This is not investment advice — consult a SEBI-registered advisor.